posteditor

posteditor

BCE Q1 2026 results to be announced May 7

B MONTRÉAL, April 2, 2026 /PRNewswire/ – BCE Inc. (TSX: BCE) (NYSE: BCE) will hold its first-quarter 2026 results conference call with the financial community… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

B AVC-203 is the world’s first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T cell therapy to enter clinical testing WATERTOWN, Mass., April 2, 2026 /PRNewswire/ —… Login to continue reading Login Sign up for complimentary access Sign Up Now Close